LondonIn breast cancer, same-class retreatment is not futile.
CDK4/6 drugs block cell-cycle proteins; a study of 78 patients found 64.5% responded longer to palbociclib after abemaciclib had stopped working.
The finding challenges the assumption of full cross-resistance; prospective trials are needed to guide treatment sequencing.
Sources: Nature